Highlights Spago Nanomedical AB

Equities

SPAG

SE0004899474

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-28 EDT			5-day change	1st Jan Change
0.332 ^SEK	-3.49%		+5.73%	+1.53%

05-20	Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	CI
05-02	Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Spago Nanomedical Provides an Update on Tumorad-01, Trial Proceeds as Planned	05-20	CI
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	04-24	CI
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-07	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-07	CI
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	01-10	CI
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis	12-20	CI
Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 in Patients with Endometriosis	12-15	CI
Spago Nanomedical AB Announces First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIA Study Within the Tumorad(R) Program	12-07	CI
Spago Nanomedical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Spago Nanomedical AB Announces Publication of Four New Patent Applications Filed with the European Patent Office	23-10-24	CI
Spago Nanomedical Announces Cancer Therapy Approved for Phase I/IIa	23-10-23	CI
Spago Nanomedical AB Receives Approval to Initiate the Clinical Phase I/IIa Study with Tumorad in Australia	23-10-19	CI
Spago Nanomedical AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02	23-06-28	CI
Spago Nanomedical AB Submits Application to Start Tumorad(R) Clinical Phase I/IIa Study	23-05-23	CI
Spago Nanomedical AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-02	CI
Spago Nanomedical AB Publishes Scientific Paper on Positive Preclinical Data with Tumorad(R) as Treatment of Solid Tumors	23-01-10	CI
First Patient Dosed in Spago Nanomedical’S Endometriosis Phase Iia Clinical Study	22-12-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Spago Nanomedical AB

Equities

SPAG

SE0004899474

Highlights

Filters